Atrophic rhinitis is a chronic, gradually progressing degenerative condition of the nasal cavity characterized by a foul odor (ozena), nasal obstruction, dryness, and crusting. The etiology of primary atrophic rhinitis is mostly unknown. Progressive metaplasia and atrophy of all mucosal components (epithelium, vessels, and glands) takes place because of increased osteoclastic activity, resulting in a volumetric decrease of sinonasal structures. The turbinate show shrinkage and the inferior turbinate is affected the most. Endoscopic inspection reveals a large, wide nasal cavity with dried mucosa. Classically, the management of patients with primary atrophic rhinitis is aimed at alleviating symptoms using nasal irrigation douche or ointment application. In 1971, Young et al proposed closure of the nostril (Young’s operation), and Saunders et al suggested endonasal microplasty (intranasal implant insertion) for the surgical management of primary atrophic rhinitis. However, Young’s operation has its demerit on the possibility of decreased patient’s quality of life.

This study hypothesises that NasoBiome spray will be able to modulate the nasal microbiome of profile of patients with Atrophic Rhinitis thereby curing the disease condition.

This is a RCT where the cases will be treated with the NasoBiome solution nasal spray and the controls will be treated with Normal saline nasal spray for a duration of 3 months after which they will be checked on several parameters like the clinical improvement, histopathological improvement, radiological improvement and microbiome profile change.